Long-term outcome in children with Hodgkin’s lymphoma: The United Kingdom Children’s Cancer Study Group HD82 trial

2007 ◽  
Vol 43 (7) ◽  
pp. 1171-1179 ◽  
Author(s):  
Michael Capra ◽  
Martin Hewitt ◽  
Martin Radford ◽  
Janis Hayward ◽  
Claire L. Weston ◽  
...  
Keyword(s):  
United Kingdom ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Cancer Study ◽  
The United Kingdom ◽  
Cancer Study Group

Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group.

1991 ◽  
Vol 9 (2) ◽  
pp. 268-273 ◽  
Author(s):  
J Raine ◽  
A Bowman ◽  
K Wallendszus ◽  
J Pritchard
Keyword(s):  
United Kingdom ◽  
Combination Chemotherapy ◽  
Wilms Tumor ◽  
Liver Function Tests ◽  
Study Group ◽  
Severe Thrombocytopenia ◽  
Cancer Study ◽  
The United Kingdom ◽  
Cancer Study Group

We have observed hepatopathy, associated with thrombocytopenia, in children receiving chemotherapy for Wilms' tumor. We have studied this hepatopathy-thrombocytopenia syndrome (HTS) in patients enrolled in the United Kingdom Childrens' Cancer Study Group (UKCCSG) Wilms' tumor trials (UKW1 and UKW2). At the time of this study, 501 patients had completed therapy. Treatment flow sheets were examined for evidence of hepatopathy (hepatomegaly with abnormal liver function tests) and severe thrombocytopenia (platelet count less than 25 x 10(9)/L). No child who developed the syndrome had received irradiation. HTS was seen in five of 355 (1.4%) of patients treated with combination chemotherapy but in none of the 146 patients treated with vincristine alone. In each instance, the onset was less than 10 weeks after diagnosis. In two children, hepatopathy was severe with jaundice, ascites, transaminases greater than 1,000 IU/L, and prolongation of prothrombin time. On average, HTS lasted 12 days, and resolved with supportive treatment. After recovery, the children tolerated chemotherapy, mostly at reduced dosage, without recurrence. There was no evident long-term morbidity. Dactinomycin is the probable cause of this syndrome. We conclude that the HTS is a rare but important complication of dactinomycin-containing combination chemotherapy for Wilms' tumor. Children developing "isolated" thrombocytopenia following dactinomycin are "at risk" of developing the full-blown syndrome and should have their treatment modified accordingly.

scholarly journals Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group.

1997 ◽  
Vol 15 (7) ◽  
pp. 2622-2630 ◽  
Author(s):  
A G Shankar ◽  
S Ashley ◽  
M Radford ◽  
A Barrett ◽  
D Wright ◽  
...  
Keyword(s):  
United Kingdom ◽  
Prognostic Factor ◽  
Relapse Rate ◽  
Stage I ◽  
Study Group ◽  
Local Irradiation ◽  
Histologic Subtype ◽  
Cancer Study ◽  
The United Kingdom ◽  
Cancer Study Group

PURPOSE Histology has been identified as an important prognostic factor in Hodgkin's disease (HD) in adults. Information regarding the impact of histology on outcome in childhood HD is scarce. This study determines the effect of histology on the overall survival (OS) or progression-free survival (PFS) in a national series of children treated in a standardized manner. PATIENTS AND METHODS The results of treatment of 331 assessable patients, treated between January 1, 1982 and June 30, 1992, in the United Kingdom Children's Cancer Study Group (UKCCSG) Hodgkin's study I were reviewed to evaluate OS, PFS, and deaths according to stage and histology. Treatment was either involved-field radiation alone (stage IA) or chlorambucil, vinblastine, procarbazine, and prednisolone (ChlVPP) chemotherapy with or without mediastinal radiation. All were clinically staged at diagnosis. RESULTS Nodular sclerosing (NS) HD was the most common histologic subtype (155 of 331 patients [47%]) and was uniformly distributed through all stages. Lymphocyte-depletion (LD) HD was extremely uncommon (< 1%). Mixed-cellularity (MC) HD had the highest relapse rate, but this was only significant (P < .05) in stage I patients who received local irradiation alone. There was no other statistically significant difference in OS and PFS between the various histologic subtypes. Multivariate analysis for PFS and OS confirmed that stage was the most important prognostic factor and that histology did not have an effect after stratification by stage. CONCLUSION This study demonstrates that with effective multiagent chemotherapy, histologic subtype does not influence outcome. The high relapse rates in stage I MC subtype indicates that MC HD is biologically aggressive and systemic treatment with or without local irradiation may be indicated. The high relapse rate in stage IV patients appeared to be independent of histology.

Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group.

1989 ◽  
Vol 7 (1) ◽  
pp. 92-99 ◽  
Author(s):  
A T Meadows ◽  
R Sposto ◽  
R D Jenkin ◽  
J H Kersey ◽  
R R Chilcote ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Similar Efficacy ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Study Population ◽  
Localized Disease

Successful treatment of localized non-Hodgkin's lymphoma (NHL) in childhood with 18 months of cyclophosphamide, vincristine, methotrexate (MTX), and prednisone (COMP) prompted a randomized clinical trial to determine whether a 6-month course of the same therapy was as effective as an 18-month course when combined with local irradiation. Two successive Childrens Cancer Study Group (CCSG) protocols (CCG 551 and CCG 501) entered 232 eligible patients from October 1979 until April 1986. Initially, all children with localized disease were considered eligible, but by a subsequent amendment, those with lymphoblastic (LB) histology were excluded. Hence, the study population consisted of 211 patients with nonlymphoblastic (NLB) and 21 with LB disease. Early relapses (before 6 months) occurred in 13 patients with NLB histology. Late relapses were seen in seven patients, three with LB histology. Among the 104 randomized patients who followed the prescribed therapy, there were four recurrences and no differences between 6-month and 18-month therapy. The overall survival for NLB disease was 91% on CCG 551 and 98% on CCG 501. We conclude that 6 months of COMP is excellent therapy for children with localized NLB NHL.

The role of surgery in abdominal non-Hodgkin's lymphoma: Experience from the childrens cancer study group

1992 ◽  
Vol 27 (2) ◽  
pp. 230-235 ◽  
Author(s):  
Michael P. LaQuaglia ◽  
Charles J.H. Stolar ◽  
Mark Krailo ◽  
Philip Exelby ◽  
Stuart Siegel ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document